Table II.
Etizolam Blood Concentrations (ng/mL) Categorized by Sample Type and Case Category (13 November 2019 –13 December 2020)*
| Antemortem serum/plasma | Antemortem blood | Postmortem femoral blooda | |||||
|---|---|---|---|---|---|---|---|
| Death investigation | Impaired driving | Death investigation | Impaired driving | Sexual assault | Traumatic death | Other | |
| Mean | 13.0 | 16.0 | 25.2 | 35.9 | 12.4 | 48.5 | 18.5 |
| Median | 6.5 | 17.2 | 21.8 | 13.8 | 13.0 | 17.1 | 7.7 |
| Range | <5–29 | 8.6–21 | <5–60 | <5–767 | 7.9–16 | 5.7–154 | <5–260 |
| n | 3 | 4 | 10 | 82b | 4 | 4 | 85 |
Antemortem samples for death investigations were collected in hospital prior to death.
Only one postmortem blood sample was not femoral blood—a heart blood sample with an etizolam concentration of <5 ng/mL.
One case excluded from statistical analysis because the concentration of etizolam was reported as >160 ng/mL.